Implications of somatostatin analogues in the treatment of acromegaly

Gariani, Karim; Meyer, Patrick; Philippe, Jacques

doi:10.17925/EE.2013.09.02.132

Scientific article

Review

Open access

English

Implications of somatostatin analogues in the treatment of acromegaly

ContributorsGariani, Karim; Meyer, Patrick; Philippe, Jacques

Published inEuropean endocrinology, vol. 9, no. 2, p. 132-135

Publication date2013

Abstract

Octreotide has an important role in the medical management of acromegaly. Its place in the management of acromegaly as an adjuvant therapy after neurosurgery is well established with a well-demonstrated efficacy. It can also be used in certain clinical conditions as a neoadjuvant treatment. Clinicians and patients should be aware of the possible side effects of octreotide treatment.

Keywords

Acromegaly
Octreotide
Side effects
Somatostatin analogues
Treatment

Affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Research group

Laboratoire de recherche NAFLD et résistance à l'insuline (997)

Citation (ISO format)

GARIANI, Karim, MEYER, Patrick, PHILIPPE, Jacques. Implications of somatostatin analogues in the treatment of acromegaly. In: European endocrinology, 2013, vol. 9, n° 2, p. 132–135. doi: 10.17925/EE.2013.09.02.132

Article (Published version)

Identifiers

PID : unige:142949
DOI : 10.17925/EE.2013.09.02.132
PMID : 29922369

Commercial URLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003582/

ISSN of the journal1758-3772

285views

158downloads

Creation08/11/2020 10:56:00 AM

First validation08/11/2020 10:56:00 AM

Update time03/15/2023 10:45:24 PM

Status update03/15/2023 10:45:24 PM

Last indexation08/30/2023 11:39:32 PM

Archive ouverte UNIGE

Implications of somatostatin analogues in the treatment of acromegaly

Technical informations